



**Heads of HTA Agencies Group**

# **MEMORANDUM OF UNDERSTANDING**

**HAG**

HEADS OF HTA  
AGENCIES GROUP

# MEMORANDUM OF UNDERSTANDING

---

## Heads of HTA Agencies Group (HAG)

This Memorandum of Understanding is entered into by and between:

1. **AGENCJA OCENY TECHNOLOGII MEDYCZNYCH I TARYFIKACJI (AOTMiT),**
2. **SLOVENIAN QUALITY HEALTH CARE AGENCY (JAKZ),**
3. **AGENZIA ITALIANA DEL FARMACO (AIFA),**
4. **AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI (AGENAS),**
5. **DACHVERBAND DER SOZIALVERSICHERUNGSTRÄGER (DVSU),**
6. **DANISH MEDICINES AGENCY (DKMA),**
7. **DANISH MEDICINES COUNCIL (DMC),**
8. **FEDERAAL KENNISCENTRUM VOOR DE GEZONDHEIDSZORG - CENTRE  
FÉDÉRAL D'EXPERTISE DES SOINS DE SANTÉ - BELGIAN HEALTH CARE  
KNOWLEDGE CENTRE (KCE),**
9. **FINNISH COORDINATING CENTER FOR HEALTH TECHNOLOGY ASSESSMENT  
(FinCCHTA),**
10. **FINNISH MEDICINES AGENCY (FIMEA),**
11. **GEMEINSAMER BUNDESAUSSCHUSS (G-BA),**
12. **GREEK HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT (HTA)  
COMMITTEE, GREEK MINISTRY OF HEALTH (GR-HTA MOH),**
13. **HAUTE AUTORITÉ DE SANTÉ (HAS),**
14. **HEALTH INFORMATION AND QUALITY AUTHORITY (HIQA),**
15. **HTA AUSTRIA, AUSTRIAN INSTITUTE FOR HEALTH TECHNOLOGY  
ASSESSMENT GMBH (AIHTA),**
16. **ICELANDIC MEDICINES AGENCY (IMA),**
17. **INFARMED-AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DE  
SAUDE, I.P. (INFARMED, I.P.), (INFARMED),**
18. **INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE (IQWiG),**
19. **NATIONAL AGENCY FOR MEDICINES AND MEDICAL DEVICES OF ROMANIA  
(NAMMDR),**

20. NATIONAL CENTER FOR PUBLIC HEALTH AND PHARMACY (NCPHP),
21. NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE),
22. NATIONAL COUNCIL ON PRICES AND REIMBURSEMENT OF MEDICINAL PRODUCTS (NCPRMP),
23. NATIONAL INSTITUTE FOR HEALTH AND DISABILITY INSURANCE (RIZIV-INAMI),
24. NATIONAL INSTITUTE FOR VALUE AND TECHNOLOGIES IN HEALTHCARE (NIHO),
25. PHARMACEUTICAL SERVICES, CYPRUS MINISTRY OF HEALTH (CYMOH),
26. REGIONE EMILIA ROMAGNA (RER),
27. SPANISH NETWORK OF AGENCIES FOR ASSESSING NATIONAL HEALTH SYSTEM TECHNOLOGIES AND PERFORMANCE (RedETS),
28. STATE AGENCY OF MEDICINES OF THE REPUBLIC OF LATVIA (SAM),
29. STATE INSTITUTE FOR DRUG CONTROL (SÚKL ),
30. STATE MEDICINES CONTROL AGENCY (SMCA),
31. SWEDISH AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT AND ASSESSMENT OF SOCIAL SERVICES (SBU),
32. THE DANISH HEALTHCARE QUALITY INSTITUTE (DHQI),
33. THE DENTAL AND PHARMACEUTICAL BENEFITS AGENCY (TLV),
34. THE NORWEGIAN MEDICAL PRODUCTS AGENCY (NOMA),
35. THE SPANISH AGENCY OF MEDICINES AND MEDICAL DEVICES (AEMPS),
36. ZORGINSTITUUT NEDERLAND (ZIN)

individually referred to as a “Party” or collectively as the “Parties”, the “HAG”, “the network” or the “Collaboration”

THE PARTIES AGREE AS FOLLOWS:

## **1. PURPOSE**

This agreement renews the formal framework for the HTA-focused collaborative network, namely the “Heads of HTA Agencies Group” or “HAG” and previously established by the first version of the memorandum of understanding signed in October 2021.

This current version replaces:

- a. The HAG Memorandum of Understanding signed on October 2021
- b. Amendment to the HAG Memorandum of Understanding Accession agreement n°1
- c. Amendment to the HAG Memorandum of Understanding Accession agreement n°2
- d. And the General Principles of Good Cooperation in the field of HTA adopted on March 17, 2022

## **2. AREAS OF COOPERATION**

The HAG is comprised of the heads of European HTA bodies or their representatives sharing a common vision: a Europe in which HTA contributes to timely, fair, and sustainable patient access to health technologies with added benefit. It shall be a high-level forum to raise and discuss strategic matters of relevance for HTA bodies across Europe. Its primary mission is to support a strong strategic partnership and to promote effective and efficient solutions for a European HTA collaboration. In undertaking its functions, the HAG should strive to ensure a high level of trust, collaboration and transparency in all processes and procedures within the group and thus towards the member organisations represented in HAG as well as in its interaction with any external parties.

Areas of Cooperation are agreed jointly through the cooperation mechanism in this Memorandum of Understanding and the HAG Strategic Plan. Policies and priorities

may be jointly reviewed by the Parties to allow the Parties to respond to newly emerging issues.

**2.1. The specific aims of the HAG are the following:**

- To facilitate dialogue and open exchange of information between EU/EEA Member States and HTA agencies
- To support the cooperation and address key strategic issues for the network, such as capacity building, work-sharing and exchange of best practices
- To advise policy makers and relevant EU and national institutions on matters regarding HTA, particularly cooperation in HTA
- To support the joint work under the [Regulation \(EU\) 2021/2282 on health technology assessment](#) (HTAR)

**2.2. Actions taken by the HAG**

Actions and strategic objectives of the HAG will be specified in a dedicated strategic plan that will be adopted in 2025 and updated in the future.

**2.3. Legal Basis**

The HAG is not a legal entity. The collaboration shall be conducted in compliance with all applicable laws and regulations, including but not limited to relevant national laws of the participating countries in general and the rules applicable to national HTA organisations in particular, as well as European Union legislation

**3. HAG MEMBERSHIP**

HAG Members shall be Heads of EU/EEA HTA bodies, agencies or departments that, from an organisational point of view, are governmental, public or standalone independent organisations connected to the healthcare system. These organisations should have appropriate HTA expertise and mandate in this field. Likewise, they should work in a scientifically independent manner at a national or regional level and should be free of conflict of interest (see section 11).

In order to have a strong strategic and guiding role in the activities of the EU HTA system, the HAG will include as many EU/EEA HTA bodies as possible. Countries outside the EU/EEA will not be represented in the HAG.

Each organisation will be represented in the HAG by its Head of agency or a high-ranked member of the organisation appointed by its Head. Individuals who have the capacity to make decisions on behalf of the Head can act as his/her substitute in the group if necessary and for a limited period of time.

The HAG is composed of “member” and “observer member” organisations.

### **3.1. Members**

To become a member of the HAG, eligible organisations can apply to the Secretariat. Applications will be reviewed by the Secretariat and the Chairs and presented to all HAG members. New memberships will be accepted following a vote by HAG (according to the agreed upon decision process detailed in paragraph 5.2 of this MEMORANDUM OF UNDERSTANDING).

Members have voting rights in all HAG activities.

### **3.2. Observer Members**

HTA bodies, agencies and departments from EU/EEA Member States that are not members of the HAG may apply as an observer member. Joining as an observer member in these situations requires approval, on a case-by-case basis, by the members at the proposal of the HAG Chairs. This participation must not exceed a single period of 12 months following the approval of their application. Although it is expected that the organisation then joins the HAG as a “member” the observer status can be renewed at the discretion of the Chairs on a case-by-case basis.

In the case of an EU/EEA Member State without an established HTA body, agency or department, an organization (e.g., Ministry of Health) from the country may apply to the HAG as an observer member. It is expected that if an HTA organization is established in the country, that body would then become a member of the HAG.

Their observer status may be renewed annually at the discretion of the HAG members on a case-by-case basis.

Observers are allowed to participate in HAG meetings but do not have voting rights.

#### **4. ROLES**

This agreement establishes the following roles as required for the functioning of the HAG.

##### **4.1. Chair and Co-Chairs**

The Chair presides over the HAG network. Once elected, the Chair acts neutrally in the best interest of the HAG as a whole.

In addition to the Chair, two co-Chairs shall be elected. The co-Chairs have similar responsibilities and can substitute for the Chair when necessary.

The remit of the HAG Chair and co-Chairs is to:

- Coordinate and facilitate the operation of the HAG.
- Supervise and manage the HAG.
- Serve as the HAG's point of contact with all stakeholders.
- Represent the network externally.

They meet monthly in a virtual meeting with the support of the designated Secretariat members.

The Chair and co-Chairs will be elected for a 3-year term. However, exceptionally, and to ensure continuity in the HAG functions, one of the co-Chairs elected in 2025 will be appointed for a two-year term. The term of office of the two co-Chairs elected in 2025 (two years or three years) will be determined by drawing lots after the elections, unless one of the two co-Chairs expresses a preference.

In the event of resignation or temporary leave of the Chair or co-Chair, a high-ranked representative from their organisation shall be appointed to carry out the duties of the Chair/co-Chair for the remainder of the term of office or the duration of their



temporary leave. If this organisation is unable to appoint a replacement for the remainder of the term of office, new elections may be organised.

Quorum and voting rules as described in section 5.1 apply to the Chair and the co-Chairs' elections.

#### **4.2. The Secretariat**

The Secretariat shall facilitate and support the work of the HAG, ensuring coordination, consistency and continuity of the work and activities of the group. The Secretariat consists of up to five different agencies, three of which are from each of the agencies that take on the responsibilities of Chair and co-Chair for the duration of their remit. Two additional agencies from the HAG network can provide one member each to the Secretariat.

The Secretariat's remit is to:

- Provide executive and administrative support to the HAG Chairs and HAG Members
- Organize in-person and on-line HAG meetings and send relevant documents to the Members in advance of these meetings
- Be responsible for communication within HAG Members and to external interested parties, after receiving directions from the HAG Chairs
- Support the HAG website functionality
- Act as collective memory by keeping updated records of agendas, minutes and decisions for HAG Chairs and HAG Meetings
- Assist/Cooperate with the EU Presidency in HTA matters
- Ensure co-ordination of the various working groups of the HAG and externally with the HTACG and the European Commission
- Report to the HAG Chairs
- Other appropriate tasks agreed by the HAG Chairs



As a general rule, the Secretariat shall use teleconferences or similar electronic means of communication on a regular basis to perform its tasks. The Secretariat meets at least once a month.

The HAG representative of the Member State holding the Presidency of the European Council is encouraged to support and work closely with the HAG Secretariat during the Presidency, particularly relating to the organisation of an in-person HAG meeting.

The Secretariat should be supported by the working groups that can be appointed by the HAG on request and when needed. The working groups are expected to focus on their dedicated topics but also to support to the Secretariat when it comes to background material for meeting agenda topics etc.

Secretariat members provided by the agencies of HAG Chairs hold office for the duration of the term of the respective Chair/co-Chair and are appointed within 30 days following the Chair's/co-Chair's election.

The remaining Secretariat members are appointed for a period of three years. Organisations shall endeavour to put resources at the disposal of the Secretariat in such a manner that continuity is upheld and foreseeing a rotation amongst member agencies. The appointment of these Secretariat members is preceded by an open call to all the agencies in the network. Nominations for HAG Secretariat shall be submitted by the respective agency stating their commitment and sent to the HAG Chairs contact point within a deadline determined.

When the term of a Secretariat member expires or a Secretariat member resigns, the HAG Chair notifies the network and opens a call. Should the Secretariat receive more applicants than open spaces, the HAG Chair and co-Chairs will decide which organisations join the Secretariat. The appointment should happen within 30 days after the call.

## **5. DECISION-MAKING PROCESS**

### **5.1. Quorum and Voting Rules**

At all meetings of the HAG, a quorum shall consist of a majority of the group, including no less than 60% of voting members.

The HAG is a consensus-driven collaboration by nature. However, when consensus is not possible, the group should reach decisions by a single majority vote of its members. Each member of the HAG shall have one vote. The Chair is responsible for leading the voting process and announcing the results of the vote. In the event of a tie, the Chair will cast the tiebreaking vote.

All HAG members' votes must be counted, whether they are present at the meeting or not. If Heads are unable to attend a meeting, they may delegate their voting power to their substitute or submit their vote via writing in advance of the meeting to the Secretariat.

### **5.2 Conflict resolution procedure**

In order to solve possible disagreements in a transparent and predictable way, the HAG will follow a series of steps to resolve conflicts:

- The disagreeing parties will present their different points of view with arguments in a meeting; the entire group discusses the issue and tries to generate a consensus.
- If consensus cannot to be reached, two individuals which may include the Chairperson, a member of the Secretariat or a respected relevant third party shall act as co-mediators, discussing the issue and suggesting (but not imposing) a resolution.

The resolution should be put together in collaboration with the disagreeing organisations, who will have the opportunity to justify their opinion and present new evidence if necessary. The entire group tries to reach a

consensus based on the co-mediators' suggestion. If consensus were not to be reached, a decision shall be based on threshold majority voting (i.e., More than 50% of the votes).

## **6 MEETING FREQUENCY**

In-person plenary meetings of the HAG shall be planned twice yearly; additional virtual meetings can be scheduled at regular intervals or an ad hoc basis.

## **7 RIGHTS AND RESPONSIBILITIES OF COLLABORATING PARTIES**

Each Party is to actively participate in the activities of the HAG and undertake all reasonable endeavours to perform and fulfil promptly, actively and on time, all its agreed upon responsibilities. Parties are to:

- Promptly notify the Secretariat of any significant problem and delay likely to affect the progress of the HAG/HAG work, and
- Inform the other Parties of relevant communication they receive from Third Parties in relation to the activities of the HAG.

## **8 ACTING ON BEHALF OF THE HAG**

The Chair and co-Chairs shall act as the main external representatives of the HAG. They shall inform the HAG members when they act on behalf of the Collaboration (e.g., when giving presentations, writing communication, using the HAG logo). In case a HAG member is invited to represent the network to an external event, they shall seek for the Chair and Co-Chair opinion and inform all parties.

Parties cannot express a view or take positions “on behalf of the Collaboration” unless clear consent of the Parties is sought and received in advance.

## **9 RIGHT TO DISAGREE WITH JOINT STATEMENTS, OPINIONS AND DOCUMENTS**

Each Party can express a divergent opinion to that of the other Parties, either motivated in writing or orally. This Party can ask to have its opinion published if it concerns a publicly available production from the HAG.

The Parties are not bound to follow the conclusions of any work that is produced jointly or to use any joint work in national settings.

## **10 CONFIDENTIALITY**

The Parties are subject to an obligation of confidentiality. By signing this Memorandum of Understanding the Parties agree to treat information shared within the HAG confidentially when appropriate, ensuring compliance with national and EU legislations.

## **11 CONFLICT OF INTEREST**

Discussion and productions of the collaboration require a high level of independence and impartiality. Therefore, the HAG is vigilant about ethics and prevention of conflict of interest. Each party must ensure that they are not in a conflict of interest situation when participating to a HAG meeting, discussion or production. Where a member considers that they have a conflict with a discussion item then they may so inform the Chair and Co-Chairs and excuse themselves from the discussion or meeting.

## **12 INTELLECTUAL PROPERTY RIGHTS**

The Parties acknowledge that nothing in this Memorandum of Understanding will affect ownership of any intellectual property rights.

A Party may, a) not use the logo of another Party unless that Party has given its prior approval in writing nor, b) promote any relationship which is beyond the remit or scope of the Memorandum of Understanding.

### **13 PROCESSING OF PERSONAL DATA BY THE PARTIES**

The Parties will process personal data in compliance with applicable EU and national law on data protection (including authorisations or notification requirements). The Parties may grant their personnel access only to data that is strictly necessary for implementing, managing and monitoring the Collaboration. Any forms completed by Members of the HAG and their representatives (e.g. meeting registration data) will be processed, stored and handled according to the requirements as set out by the EU's General Data Protection Regulation Regulation (EU) 2016/679.

### **14 FINANCE & RESOURCES**

Any costs that may arise from the common activities, such as the management and maintenance of the HAG website, will be assumed by the Chair's organisation. After the adoption of this Memorandum of Understanding, consideration will be given to sharing these common costs among all parties.

Costs related to the organisation of in-person HAG meetings are assumed by the host organisation(s), with the exception of travel and accommodation expenses, which will be covered by each Party.

All costs associated with the work of the Chair and co-Chairs as well as the HAG Secretariat, including any participation in the HAG meetings, are covered by the respective agencies.

Other potential costs (e.g. Involvement in a working group) must be covered by each party.

### **15. LIABILITY**

#### **15.1. Liability of the Parties towards each other**

As regards to any claims or damages arising in connection with the preparation and performance of the activities of the HAG, the following liability provision shall apply:

No Party shall be responsible to another Party for indirect or consequential loss or damages such as, but not limited to, loss of profits, anticipated savings, opportunity, reputation or goodwill, loss of revenue or loss of contracts.

#### **15.2. Liability towards Third Parties**

Each Party shall be solely liable for any loss, damage or injury to Third Parties resulting from the execution of its assigned tasks in the HAG and from its use of knowledge and/or pre-existing know-how.

#### **16. EFFICACY AND DURATION**

This Memorandum of Understanding will become effective when signed by all Parties.

The HAG will evaluate the need to revise this Memorandum of Understanding when necessary and at least every three years (from the point of entry into force).

#### **17. TERMINATION AND MODIFICATION**

A Party may, at any time, withdraw from the Collaboration and terminate its involvement in the activities set out in this without having to communicate the reason for withdrawal. The notice period for such a withdrawal is 30 calendar days.

Notwithstanding the foregoing, it is agreed that any termination of this Memorandum of Understanding shall be without prejudice to: (i) the orderly completion of any ongoing collaborative activity; and (ii) any other rights and responsibilities of the Parties accrued prior to the date of termination.

This Memorandum of Understanding may be modified by mutual consent of the Parties as expressed in writing.

IN WITNESS THEREFORE, the Parties hereto have caused this MEMORANDUM OF UNDERSTANDING to be executed as of the date stated below.

FOR

**1. AGENCJA OCENY TECHNOLOGII MEDYCZNYCH I TARYFIKACJI, (AOTMiT)**

*Daniel Rutkowski*

Daniel Rutkowski (Oct 22, 2025 10:45:21 GMT+2)

Daniel Rutkowski, President

**2. SLOVENIAN QUALITY HEALTH CARE AGENCY (JAKZ)**

*Katarina Beravs-Bervar*

Katarina Beravs-Bervar, Deputy-Director

**3. AGENZIA ITALIANA DEL FARMACO, (AIFA)**

*Prof. Robert Giovanni Nisticò*

Prof. Robert Giovanni Nisticò (Oct 6, 2025 16:11:01 GMT+2)

Robert Giovanni Nisticò, Chairperson



**4. AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI, (AGENAS)**



Americo Cicchetti (Oct 2, 2025 17:30:00 GMT+2)

Americo Cicchetti, Special Commissioner

**5. DACHVERBAND DER SOZIALVERSICHERUNGSTRÄGER, (DVS)**



Jan Pazourek (Oct 10, 2025 09:12:15 GMT+2)

Mag. Jan Pazourek, Director

**6. DANISH MEDICINES AGENCY, (DKMA)**



Kim Helleberg Madsen (Oct 7, 2025 08:21:30 GMT+2)

Kim Helleberg Madsen, Director of Division

**7. DANISH MEDICINES COUNCIL, (DMC)**



Søren Gaard (Oct 2, 2025 21:47:42 GMT+2)

Søren Gaard, Chief Executive Officer (CEO)

**8. FEDERAAL KENNISCENTRUM VOOR DE GEZONDHEIDSZORG - CENTRE FÉDÉRAL  
D'EXPERTISE DES SOINS DE SANTÉ - BELGIAN HEALTH CARE KNOWLEDGE CENTRE,  
(KCE)**



Ann Van den Bruel (Oct 9, 2025 16:22:37 GMT+2)

Ann Van den Bruel, General Director

**9. FINNISH COORDINATING CENTER FOR HEALTH TECHNOLOGY ASSESSMENT,  
(FinCCHTA)**



Teija Kekonen (Oct 2, 2025 14:03:04 GMT+3)


Teija Kekonen, Director of Research, Development and Innovation

**10. FINNISH MEDICINES AGENCY, (FIMEA)**

  
Eija Pelkonen (Oct 3, 2025 15:05:34 GMT+3)

Eija Pelkonen, Director General

**11. GEMEINSAMER BUNDESAUSSCHUSS, (G-BA)**



Josef Hecken, Chairman

**12. GREEK HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT (HTA) COMMITTEE, GREEK MINISTRY OF HEALTH, (GR-HTA MOH)**

  
F Bacopoulou (Oct 3, 2025 01:10:42 GMT+3)

Flora Bacopoulou, Chair

**13. HAUTE AUTORITÉ DE SANTÉ, (HAS)**



COLLET (Oct 2, 2025 17:00:55 GMT+2)

Lionel Collet, President

**14. HEALTH INFORMATION AND QUALITY AUTHORITY, (HIQA)**



Angela Fitzgerald (Oct 6, 2025 18:19:58 GMT+1)

Angela Fitzgerald, CEO


**15. HTA AUSTRIA, AUSTRIAN INSTITUTE FOR HEALTH TECHNOLOGY ASSESSMENT GMBH, (AIHTA)**



Ingrid Zechmeister-Koss (Oct 2, 2025 08:31:59 GMT+2)

Ingrid Zechmeister-Koss, Director

**16. ICELANDIC MEDICINES AGENCY, (IMA)**



[Runa Hauksdottir Hvannberg \(Oct 3, 2025 12:30:11 GMT\)](#)

Runa Hauksdottir Hvannberg, Executive Director

**17. INFARMED - AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DE SAUDE,  
I.P (INFARMED)**



[Rui Santos Ivo \(Oct 2, 2025 12:07:38 GMT+1\)](#)

Rui Santos Ivo, President

**18. INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE, (IQWiG)**



[Thomas Kaiser \(Oct 8, 2025 09:00:29 GMT+2\)](#)

Thomas Kaiser, Director

**19. NATIONAL AGENCY FOR MEDICINES AND MEDICAL DEVICES OF ROMANIA,  
(NAMMDR)**

*Răzvan Prisada*

Răzvan Prisada (Oct 12, 2025 23:17:53 GMT+3)

Razvan Mihai Prisada, President

**20. NATIONAL CENTER FOR PUBLIC HEALTH AND PHARMACY, (NCPHP)**

*Orsolya Surján*

Orsolya Surján (Oct 3, 2025 16:12:55 GMT+2)

Orsolya Surján, Chief Medical Officer

*Timár Tünde*

Timár Tünde (Oct 3, 2025 14:45:48 GMT+2)

Tünde Timar, Chief Financial Officer

**21. NATIONAL CENTRE FOR PHARMACOECONOMICS, (NCPE)**

*Roisin Adams*

Roisin Adams (Oct 10, 2025 20:17:39 GMT+1)

Roisin Adams, Head of HTA Strategy and External Engagement

**22. NATIONAL COUNCIL ON PRICES AND REIMBURSEMENT OF MEDICINAL PRODUCTS, (NCPRMP)**

*Silvia Terezova*

Silvia Terezova (Oct 7, 2025 15:51:53 GMT+3)

Silvia Terezova, Chair

**23. NATIONAL INSTITUTE FOR HEALTH AND DISABILITY INSURANCE, (RIZIV-INAMI)**

*Pedro FACON*

Pedro FACON (Oct 2, 2025 15:25:02 GMT+2)

Pedro Facon, Deputy Chief Executive Officer (CEO)

**24. NATIONAL INSTITUTE FOR VALUE AND TECHNOLOGIES IN HEALTHCARE, (NIHO)**

*Tomas Tesar*

Tomas Tesar (Oct 6, 2025 09:44:38 GMT+2)

Tomas Tesar, PhD., Director



**25. PHARMACEUTICAL SERVICES, CYPRUS MINISTRY OF HEALTH, (CYMOH)**

*Helena Panayiotopoulou*

Helena Panayiotopoulou (Oct 2, 2025 14:06:40 GMT+3)

Helena Panayiotopoulou, Director

**26. REGIONE EMILIA ROMAGNA, (RER)**

*Elisa Sangiorgi*

Elisa Sangiorgi, Director of Medical Device HTA Centre

**27. SPANISH NETWORK OF AGENCIES FOR ASSESSING NATIONAL HEALTH SYSTEM TECHNOLOGIES AND PERFORMANCE, (RedETS)**

*Lilisbeth Perestelo-Perez*

Lilisbeth Perestelo-Perez (Oct 2, 2025 15:16:17 GMT+1)


Lilisbeth Perestelo-Perez Director of the HTA Agency for the Canary Islands Health Service (SESCS), President of RedETS

**28. STATE AGENCY OF MEDICINES OF THE REPUBLIC OF LATVIA, (SAM)**



Sergejs Akuličs, Deputy Director in Pharmaceuticals

**29. STATE INSTITUTE FOR DRUG CONTROL, (SÚKL)**



Tomáš Boráň, Head

**30. STATE MEDICINES CONTROL AGENCY, (SMCA)**



Dovile Marcinke (Oct 23, 2025 18:10:13 GMT+3)

Dovilė Marcinkė, Director

**31. SWEDISH AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT AND ASSESSMENT OF SOCIAL SERVICES, (SBU)**

*Britta Björkholm*

Britta Björkholm, Director General

**32. THE DANISH HEALTHCARE QUALITY INSTITUTE, (DHQI)**

*Jens Winther Jensen*

Jens Winther Jensen, Chief Executive Officer (CEO)

**33. THE DENTAL AND PHARMACEUTICAL BENEFITS AGENCY, (TLV)**

*Agneta Karlsson*

[Agneta Karlsson \(Oct 15, 2025 11:19:01 GMT+2\)](#)

Agneta Karlsson, Director General

**34. THE NORWEGIAN MEDICAL PRODUCTS AGENCY, (NOMA)**

*Trygve Ottersen*

Trygve Ottersen (Oct 6, 2025 21:18:36 GMT+2)

Trygve Ottersen, Director General

**35. THE SPANISH AGENCY OF MEDICINES AND MEDICAL DEVICES, (AEMPS)**

*María Jesús Lamas*

María Jesús Lamas Díaz, Executive Director

**36. ZORGINSTITUUT NEDERLAND, (ZIN)**



M. J. Janssen, Director General